

Marco Agostini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1234302/publications.pdf>

Version: 2024-02-01

140
papers

3,507
citations

136950

32
h-index

175258

52
g-index

148
all docs

148
docs citations

148
times ranked

6628
citing authors

#	ARTICLE	IF	CITATIONS
1	Decellularized normal and cancer tissues as tools for cancer research. <i>Cancer Gene Therapy</i> , 2022, 29, 879-888.	4.6	13
2	Metachronous colorectal cancer have a similar microsatellite instability frequency but a lower infiltration of lymphomononuclear cells than primary lesions. <i>Surgery</i> , 2022, 171, 1605-1611.	1.9	1
3	Establishment of a human 3D pancreatic ductal adenocarcinoma model based on a patient-derived extracellular matrix scaffold. <i>European Journal of Surgical Oncology</i> , 2022, 48, e135.	1.0	0
4	An investigation on [5 fluorouracil and epigallocatechin-3-gallate] complex activity on HT-29 cell death and its stability in gastrointestinal fluid. <i>Oncotarget</i> , 2022, 13, 476-489.	1.8	3
5	A method for assessing plasma free fatty acids from C2 to C18 and its application for the early detection of colorectal cancer. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2022, 215, 114762.	2.8	5
6	Latest Advances in Biomimetic Cell Membrane-Coated and Membrane-Derived Nanovectors for Biomedical Applications. <i>Nanomaterials</i> , 2022, 12, 1543.	4.1	16
7	Increased Tenascin C, Osteopontin and HSP90 Levels in Plasmatic Small Extracellular Vesicles of Pediatric ALK-Positive Anaplastic Large Cell Lymphoma: New Prognostic Biomarkers?. <i>Diagnostics</i> , 2021, 11, 253.	2.6	4
8	Integration of Flexibility from Distributed Energy Resources: Mapping the Innovative Italian Pilot Project UVAM. <i>Energies</i> , 2021, 14, 1910.	3.1	14
9	An electrospray ionization study on complexes of amylin with Cu(II) and Cu(I). <i>Journal of Mass Spectrometry</i> , 2021, 56, e4773.	1.6	1
10	Role of mass spectrometry in the study of interactions between amylin and metal ions. <i>Mass Spectrometry Reviews</i> , 2021, , .	5.4	2
11	Mass spectrometry in the study of molecular complexes between 5-Fluorouracil and catechins. <i>Journal of Mass Spectrometry</i> , 2021, 56, e4682.	1.6	3
12	Tumor Cells and the Extracellular Matrix Dictate the Pro-Tumoral Profile of Macrophages in CRC. <i>Cancers</i> , 2021, 13, 5199.	3.7	6
13	Nanodelivery Systems Face Challenges and Limitations in Bone Diseases Management. <i>Advanced Therapeutics</i> , 2021, 4, 2100152.	3.2	3
14	A rhabdomyosarcoma hydrogel model to unveil cell-extracellular matrix interactions. <i>Biomaterials Science</i> , 2021, 10, 124-137.	5.4	3
15	BTK inhibitors synergise with 5-FU to treat drug-resistant TP53-null colon cancers. <i>Journal of Pathology</i> , 2020, 250, 134-147.	4.5	23
16	Evidence of noncovalent complexes in some natural extracts: Ceylon tea and mate extracts. <i>Journal of Mass Spectrometry</i> , 2020, 55, e4459.	1.6	2
17	Intrinsic and Extrinsic Modulators of the Epithelial to Mesenchymal Transition: Driving the Fate of Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2020, 10, 1122.	2.8	18
18	Voltammetric responses at modified electrodes and aggregation effects of two anticancer molecules: irinotecan and sunitinib. <i>New Journal of Chemistry</i> , 2020, 44, 18233-18241.	2.8	3

#	ARTICLE	IF	CITATIONS
19	Patient-derived ECM-scaffolds of colorectal cancer and liver metastases as organotypic 3D model of liver metastatic colonization. <i>Journal of Hepatology</i> , 2020, 73, S642-S643.	3.7	0
20	Tryptophan Catabolism and Response to Therapy in Locally Advanced Rectal Cancer (LARC) Patients. <i>Frontiers in Oncology</i> , 2020, 10, 583228.	2.8	6
21	Recellularized Colorectal Cancer Patient-Derived Scaffolds as In Vitro Pre-Clinical 3D Model for Drug Screening. <i>Cancers</i> , 2020, 12, 681.	3.7	32
22	Carcinoma and Sarcoma Microenvironment at a Glance: Where We Are. <i>Frontiers in Oncology</i> , 2020, 10, 76.	2.8	20
23	Circulating microRNA expression profiling revealed miR-92a-3p as a novel biomarker of Barrett's carcinogenesis. <i>Pathology Research and Practice</i> , 2020, 216, 152907.	2.3	17
24	miR-27a is a master regulator of metabolic reprogramming and chemoresistance in colorectal cancer. <i>British Journal of Cancer</i> , 2020, 122, 1354-1366.	6.4	38
25	Leveraging Demand Flexibility by Exploiting Prosumer Response to Price Signals in Microgrids. <i>Energies</i> , 2020, 13, 3078.	3.1	7
26	Patient-Derived Scaffolds of Colorectal Cancer Metastases as an Organotypic 3D Model of the Liver Metastatic Microenvironment. <i>Cancers</i> , 2020, 12, 364.	3.7	44
27	MASS SPECTROMETRY FOR A HOLISTIC VIEW OF NATURAL EXTRACTS OF PHYTOTHERAPEUTIC INTEREST. <i>Mass Spectrometry Reviews</i> , 2020, 39, 553-573.	5.4	3
28	Recent Advances in Understanding the Protein Corona of Nanoparticles and in the Formulation of "Stealthy" Nanomaterials. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 166.	4.1	212
29	Circulating Biomarkers for Response Prediction of Rectal Cancer to Neoadjuvant Chemoradiotherapy. <i>Current Medicinal Chemistry</i> , 2020, 27, 4274-4294.	2.4	10
30	Concurrent control of MV and LV networks for ancillary services provision. , 2019, , .		0
31	Nanovectors Design for Theranostic Applications in Colorectal Cancer. <i>Journal of Oncology</i> , 2019, 2019, 1-27.	1.3	20
32	PC.01.9 ESOPHAGEAL MICROBIOTA COMPOSITION ACROSS BARRETT'S ESOPHAGUS-DYSPLASIA-EAC SEQUENCE. <i>Digestive and Liver Disease</i> , 2019, 51, e75.	0.9	0
33	Ancillary services provision by aggregators and impact on distribution network operation. , 2019, , .		3
34	Tryptophan Metabolism as Source of New Prognostic Biomarkers for FAP Patients. <i>International Journal of Tryptophan Research</i> , 2019, 12, 117864691989029.	2.3	5
35	New Mass Spectrometric Approaches for the Quantitative Evaluation of Anticancer Drug Levels in Treated Patients. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 1-10.	2.0	6
36	Preclinical three-dimensional colorectal cancer model: The next generation of in vitro drug efficacy evaluation. <i>Journal of Cellular Physiology</i> , 2019, 234, 181-191.	4.1	22

#	ARTICLE	IF	CITATIONS
37	The role of mass spectrometry in studies of glycation processes and diabetes management. <i>Mass Spectrometry Reviews</i> , 2019, 38, 112-146.	5.4	15
38	miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis. <i>Translational Oncology</i> , 2019, 12, 282-291.	3.7	14
39	Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. <i>Nature Genetics</i> , 2018, 50, 219-228.	21.4	139
40	miR-194 as predictive biomarker of responsiveness to neoadjuvant chemoradiotherapy in patients with locally advanced rectal adenocarcinoma. <i>Journal of Clinical Pathology</i> , 2018, 71, 344-350.	2.0	29
41	Decellularized colorectal cancer matrix as bioactive microenvironment for in vitro 3D cancer research. <i>Journal of Cellular Physiology</i> , 2018, 233, 5937-5948.	4.1	61
42	Inflammation and Cancer: In Medio Stat Nano. <i>Current Medicinal Chemistry</i> , 2018, 25, 4208-4223.	2.4	22
43	Reduced Plasma Levels of Very-Long-Chain Dicarboxylic Acid 28:4 in Italian and Brazilian Colorectal Cancer Patient Cohorts. <i>Metabolites</i> , 2018, 8, 91.	2.9	7
44	Experimental Evidence of the Presence of Bimolecular Caffeine/Catechin Complexes in Green Tea Extracts. <i>Journal of Natural Products</i> , 2018, 81, 2338-2347.	3.0	14
45	OC.14.1 IS THE ADHERENCE TO WCRF/AICR RECOMMENDATIONS INVOLVED IN BARRETT'S ESOPHAGUS ONSET AND ITS PROGRESSION TO EAC? A RETROSPECTIVE ANALYSIS IN A HIGH-RISK POPULATION. <i>Digestive and Liver Disease</i> , 2018, 50, e103.	0.9	0
46	Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases. <i>Cancer Cell International</i> , 2018, 18, 131.	4.1	7
47	Long non-coding RNA and extracellular matrix: the hidden players in cancer-stroma cross-talk. <i>Non-coding RNA Research</i> , 2018, 3, 174-177.	4.6	30
48	Liposomal delivery of a Pin1 inhibitor complexed with cyclodextrins as new therapy for high-grade serous ovarian cancer. <i>Journal of Controlled Release</i> , 2018, 281, 1-10.	9.9	29
49	Analytical aspects of sunitinib and its geometric isomerism towards therapeutic drug monitoring in clinical routine. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 160, 360-367.	2.8	23
50	Diagnostic Devices for Circulating Biomarkers Detection and Quantification. <i>Current Medicinal Chemistry</i> , 2018, 25, 4304-4327.	2.4	4
51	Mass spectrometry in the pharmacokinetic studies of anticancer natural products. <i>Mass Spectrometry Reviews</i> , 2017, 36, 213-251.	5.4	17
52	Gene and MicroRNA Expression Are Predictive of Tumor Response in Rectal Adenocarcinoma Patients Treated With Preoperative Chemoradiotherapy. <i>Journal of Cellular Physiology</i> , 2017, 232, 426-435.	4.1	54
53	Insulin promotes HER2 signaling activation during Barrett's Esophagus carcinogenesis. <i>Digestive and Liver Disease</i> , 2017, 49, 630-638.	0.9	8
54	Bottom-up synthesis of carbon nanoparticles with higher doxorubicin efficacy. <i>Journal of Controlled Release</i> , 2017, 248, 144-152.	9.9	51

#	ARTICLE	IF	CITATIONS
55	Field-Assisted paper spray mass spectrometry for therapeutic drug monitoring: 1. the case of imatinib in plasma. <i>Journal of Mass Spectrometry</i> , 2017, 52, 283-289.	1.6	4
56	P.08.4: Prevention of Esophageal Adenocarcinoma in Barrett's Esophagus Patients: A Moderate Calorie-Protein Restriction Program (CARE-PRO). <i>Digestive and Liver Disease</i> , 2017, 49, e180.	0.9	0
57	A Specific Mutational Signature Associated with DNA 8-Oxoguanine Persistence in MUTYH-defective Colorectal Cancer. <i>EBioMedicine</i> , 2017, 20, 39-49.	6.1	170
58	Medium chain fatty acids in intrauterine growth restricted and small for gestational age pregnancies. <i>Metabolomics</i> , 2017, 13, 1.	3.0	9
59	Diagnostic and prognostic role of cell-free DNA testing for colorectal cancer patients. <i>International Journal of Cancer</i> , 2017, 140, 1888-1898.	5.1	96
60	Immunonutrition before esophagectomy: Impact on immune surveillance mechanisms. <i>Tumor Biology</i> , 2017, 39, 101042831772868.	1.8	8
61	Engineered biomimetic nanovesicles show intrinsic anti-inflammatory properties for the treatment of inflammatory bowel diseases. <i>Nanoscale</i> , 2017, 9, 14581-14591.	5.6	57
62	BRAF p.V600E-specific immunohistochemical assessment in colorectal cancer endoscopy biopsies is consistent with the mutational profiling. <i>Histopathology</i> , 2017, 71, 1008-1011.	2.9	8
63	Tryptophan metabolism along the kynurenine and serotonin pathways reveals substantial differences in colon and rectal cancer. <i>Metabolomics</i> , 2017, 13, 1.	3.0	20
64	Extracellular Matrix and Colorectal Cancer: How Surrounding Microenvironment Affects Cancer Cell Behavior?. <i>Journal of Cellular Physiology</i> , 2017, 232, 967-975.	4.1	108
65	Serp1B3 upregulates the Cyclooxygenase-2 / β -Catenin positive loop in colorectal cancer. <i>Oncotarget</i> , 2017, 8, 15732-15743.	1.8	15
66	Circulating Cell-Free DNA in Dogs with Mammary Tumors: Short and Long Fragments and Integrity Index. <i>PLoS ONE</i> , 2017, 12, e0169454.	2.5	32
67	Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1482.	4.1	12
68	Altered plasma levels of decanoic acid in colorectal cancer as a new diagnostic biomarker. <i>Analytical and Bioanalytical Chemistry</i> , 2016, 408, 6321-6328.	3.7	37
69	Alterations of the Plasma Peptidome Profiling in Colorectal Cancer Progression. <i>Journal of Cellular Physiology</i> , 2016, 231, 915-925.	4.1	15
70	miR-19a and SOCS-1 expression in the differential diagnosis of laryngeal (glottic) verrucous squamous cell carcinoma. <i>Journal of Clinical Pathology</i> , 2016, 69, 415-421.	2.0	16
71	p53BTK targeting restores the apoptotic response to chemotherapy of p53-null drug-resistant colon cancer cells. <i>European Journal of Cancer</i> , 2016, 69, S140.	2.8	3
72	Field-Assisted Paper Spray Mass Spectrometry for the Quantitative Evaluation of Imatinib Levels in Plasma. <i>European Journal of Mass Spectrometry</i> , 2016, 22, 217-228.	1.0	4

#	ARTICLE	IF	CITATIONS
73	Cross-validation of a mass spectrometric-based method for the therapeutic drug monitoring of irinotecan: implementation of matrix-assisted laser desorption/ionization mass spectrometry in pharmacokinetic measurements. <i>Analytical and Bioanalytical Chemistry</i> , 2016, 408, 5369-5377.	3.7	10
74	Peptide Patterns as Discriminating Biomarkers in Plasma of Patients With Familial Adenomatous Polyposis. <i>Clinical Colorectal Cancer</i> , 2016, 15, e75-e92.	2.3	7
75	Predictive role of microRNA-related genetic polymorphisms in the pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. <i>Oncotarget</i> , 2016, 7, 19781-19793.	1.8	14
76	Serum miR-125b is a non-invasive predictive biomarker of the pre-operative chemoradiotherapy responsiveness in patients with rectal adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 28647-28657.	1.8	61
77	An Advanced Lithium-Sulfur Battery for High Energy Storage. <i>Advanced Energy Materials</i> , 2015, 5, 1500481.	19.5	97
78	The development of a matrix-assisted laser desorption/ionization (MALDI)-based analytical method for determination of irinotecan levels in human plasma: preliminary results. <i>Journal of Mass Spectrometry</i> , 2015, 50, 959-962.	1.6	5
79	An integrative approach for the identification of prognostic and predictive biomarkers in rectal cancer. <i>Oncotarget</i> , 2015, 6, 32561-32574.	1.8	45
80	Evaluation of cell-free DNA as a biomarker for pancreatic malignancies. <i>International Journal of Biological Markers</i> , 2015, 30, 136-141.	1.8	39
81	Enabling cytoplasmic delivery and organelle targeting by surface modification of nanocarriers. <i>Nanomedicine</i> , 2015, 10, 1923-1940.	3.3	70
82	A functional biological network centered on XRCC3: a new possible marker of chemoradiotherapy resistance in rectal cancer patients. <i>Cancer Biology and Therapy</i> , 2015, 16, 1160-1171.	3.4	49
83	Clinical Predictive Circulating Peptides in Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy. <i>Journal of Cellular Physiology</i> , 2015, 230, 1822-1828.	4.1	17
84	Next-generation sequencing for genetic testing of familial colorectal cancer syndromes. <i>Hereditary Cancer in Clinical Practice</i> , 2015, 13, 18.	1.5	31
85	MicroRNAs as Tools and Effectors for Patient Treatment in Gastrointestinal Carcinogenesis. <i>Current Drug Targets</i> , 2015, 16, 383-392.	2.1	18
86	Biomarker Signature Discovery from Mass Spectrometry Data. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2014, 11, 766-772.	3.0	12
87	NOTCH3 Signaling Regulates MUSASHI-1 Expression in Metastatic Colorectal Cancer Cells. <i>Cancer Research</i> , 2014, 74, 2106-2118.	0.9	56
88	Matrix-Assisted Laser Desorption/Ionization, Nanostructure-Assisted Laser Desorption/Ionization and Carbon Nanohorns in the Detection of Antineoplastic Drugs. 1. The Cases of Irinotecan, Sunitinib and 6-Alpha-Hydroxy Paclitaxel. <i>European Journal of Mass Spectrometry</i> , 2014, 20, 445-459.	1.0	7
89	Circulating miR-182 is a biomarker of colorectal adenocarcinoma progression. <i>Oncotarget</i> , 2014, 5, 6611-6619.	1.8	53
90	Predictive response biomarkers in rectal cancer neoadjuvant treatment. <i>Frontiers in Bioscience - Scholar</i> , 2014, S6, 110-119.	2.1	26

#	ARTICLE	IF	CITATIONS
91	Factors affecting the treatment of multiple colorectal adenomas. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2013, 27, 207-213.	2.4	5
92	Circulating cell-free DNA, SLC5A8 and SLC26A4 hypermethylation, BRAFV600E: A non-invasive tool panel for early detection of thyroid cancer. <i>Biomedicine and Pharmacotherapy</i> , 2013, 67, 723-730.	5.6	59
93	A prognostic role for Nm23-H1 in laryngeal carcinoma treated with postoperative radiotherapy: an introductory investigation. <i>European Archives of Oto-Rhino-Laryngology</i> , 2013, 270, 197-203.	1.6	4
94	OC.06.4 INSULIN SIGNALING IN BARRETT'S ESOPHAGUS: IN VITRO AND IN PATIENTS STUDIES. <i>Digestive and Liver Disease</i> , 2013, 45, S69-S70.	0.9	0
95	Clinical and molecular features of attenuated adenomatous polyposis in northern Italy. <i>Techniques in Coloproctology</i> , 2013, 17, 79-87.	1.8	12
96	<i>MUTYH</i> c.933+3A>C, associated with a severely impaired gene expression, is the first Italian founder mutation in <i>MUTYH</i> -Associated Polyposis. <i>International Journal of Cancer</i> , 2013, 132, 1060-1069.	5.1	16
97	Telomerase is an independent prognostic marker of overall survival in patients with colorectal cancer. <i>British Journal of Cancer</i> , 2013, 108, 278-284.	6.4	56
98	High Risk of Rectal Cancer and of Metachronous Colorectal Cancer in Probandes of Families Fulfilling the Amsterdam Criteria. <i>Annals of Surgery</i> , 2013, 257, 900-904.	4.2	27
99	Multivariate Analysis Approach to the Serum Peptide Profile of Morbidly Obese Patients. <i>Disease Markers</i> , 2013, 34, 269-278.	1.3	0
100	Multivariate analysis approach to the serum peptide profile of morbidly obese patients. <i>Disease Markers</i> , 2013, 34, 269-78.	1.3	0
101	Circulating cell-free DNA: A promising marker of regional lymphonode metastasis in breast cancer patients. <i>Cancer Biomarkers</i> , 2012, 11, 89-98.	1.7	68
102	APC1307K Mutations and Forkhead Box Gene (FOXO1A): Another Piece of an Interesting Correlation. <i>International Journal of Biological Markers</i> , 2012, 27, 13-19.	1.8	4
103	Telomere-Specific Reverse Transcriptase (hTERT) and Cell-free RNA in Plasma as Predictors of Pathologic Tumor Response in Rectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy. <i>Annals of Surgical Oncology</i> , 2012, 19, 3089-3096.	1.5	61
104	Serum seleno-proteins status for colorectal cancer screening explored by data mining techniques - a multidisciplinary pilot study. <i>Microchemical Journal</i> , 2012, 105, 124-132.	4.5	17
105	Multiplexed Protein Signal Pathway Mapping Identifies Patients With Rectal Cancer That Responds to Neoadjuvant Treatment. <i>Clinical Colorectal Cancer</i> , 2012, 11, 268-274.	2.3	6
106	Soft tissue sarcoma and the hereditary non-polyposis colorectal cancer (HNPCC) syndrome: formulation of an hypothesis. <i>Molecular Biology Reports</i> , 2012, 39, 9307-9310.	2.3	13
107	PKH26 Staining Defines Distinct Subsets of Normal Human Colon Epithelial Cells at Different Maturation Stages. <i>PLoS ONE</i> , 2012, 7, e43379.	2.5	10
108	Clinical and molecular detection of inherited colorectal cancers in northeast Italy. <i>Tumor Biology</i> , 2012, 33, 857-864.	1.8	3

#	ARTICLE	IF	CITATIONS
109	Survivin and laryngeal carcinoma prognosis: nuclear localization and expression of splice variants. <i>Histopathology</i> , 2012, 61, 247-256.	2.9	20
110	Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy. <i>Pharmacogenomics Journal</i> , 2011, 11, 214-226.	2.0	63
111	Circulating Cell-Free DNA: A Promising Marker of Pathologic Tumor Response in Rectal Cancer Patients Receiving Preoperative Chemoradiotherapy. <i>Annals of Surgical Oncology</i> , 2011, 18, 2461-2468.	1.5	114
112	Integrated analysis of unclassified variants in mismatch repair genes. <i>Genetics in Medicine</i> , 2011, 13, 115-124.	2.4	34
113	Rectum-Sparing Surgery May be Appropriate for Biallelic MutYH-Associated Polyposis. <i>Diseases of the Colon and Rectum</i> , 2010, 53, 1670-1675.	1.3	13
114	A ten markers panel provides a more accurate and complete microsatellite instability analysis in mismatch repair-deficient colorectal tumors. <i>Cancer Biomarkers</i> , 2010, 6, 49-61.	1.7	22
115	miRNAs in colon and rectal cancer: A consensus for their true clinical value. <i>Clinica Chimica Acta</i> , 2010, 411, 1181-1186.	1.1	40
116	Abstract LB-214: Identification of patients with adenomas or early- and late-stage colon carcinomas using nanoporous silica chips for protein profiling. , 2010, , .		0
117	Evaluation of Cell-free DNA in Urine as a Marker for Bladder Cancer Diagnosis. <i>International Journal of Biological Markers</i> , 2009, 24, 147-155.	1.8	22
118	MALDI-MS-NIST library approach for colorectal cancer diagnosis. <i>Rapid Communications in Mass Spectrometry</i> , 2009, 23, 2839-2845.	1.5	13
119	Evaluation of cell-free DNA in urine as a marker for bladder cancer diagnosis. <i>International Journal of Biological Markers</i> , 2009, 24, 147-155.	1.8	20
120	Proximal colon cancer in patients aged 51-60 years of age should be tested for microsatellites instability. A comment on the Revised Bethesda Guidelines. <i>International Journal of Colorectal Disease</i> , 2008, 23, 801-806.	2.2	17
121	Glutathione S-Transferase P1Ile105Val Polymorphism is Associated with Haematological Toxicity in Elderly Rectal Cancer Patients Receiving Preoperative Chemoradiotherapy. <i>Drugs and Aging</i> , 2008, 25, 531-539.	2.7	14
122	The role of MYH gene in genetic predisposition to colorectal cancer: Another piece of the puzzle. <i>Cancer Letters</i> , 2008, 268, 308-313.	7.2	23
123	Relationship Between Tumor and Plasma Levels of hTERT mRNA in Patients with Colorectal Cancer: Implications for Monitoring of Neoplastic Disease. <i>Clinical Cancer Research</i> , 2008, 14, 7444-7451.	7.0	82
124	Long-term follow-up after endoscopic forceps biopsies for early stage duodenal carcinoid: case report and review of endoscopic treatments. <i>Endoscopy</i> , 2007, 39, E128-E128.	1.8	4
125	P72 FOXO1A and plasma low molecular weight proteins determination: a promising diagnostic approach and biomarker for colorectal tumors. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 19.	2.2	0
126	Determining Therapeutic Approaches in the Elderly with Rectal Cancer. <i>Drugs and Aging</i> , 2007, 24, 781-790.	2.7	9

#	ARTICLE	IF	CITATIONS
127	An investigation on the nature of the peptide atm/z 904, overexpressed in plasma of patients with colorectal cancer and familial adenomatous polyposis. <i>Journal of Mass Spectrometry</i> , 2007, 42, 1606-1612.	1.6	7
128	Reply to Jaskowski et al. <i>European Journal of Human Genetics</i> , 2007, 15, 141-142.	2.8	2
129	A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 817-824.	1.5	54
130	Stability of BAT26 in tumours of hereditary nonpolyposis colorectal cancer patients with MSH2 intragenic deletion. <i>European Journal of Human Genetics</i> , 2006, 14, 63-68.	2.8	39
131	Multivariate analysis approach to the plasma protein profile of patients with advanced colorectal cancer. <i>Journal of Mass Spectrometry</i> , 2006, 41, 1546-1553.	1.6	25
132	Rectal cancer neoadjuvant treatment in elderly patients. <i>Anticancer Research</i> , 2006, 26, 3913-23.	1.1	24
133	Search of plasma markers for colorectal cancer by matrix-assisted laser desorption/ionization mass spectrometry. <i>Journal of Mass Spectrometry</i> , 2005, 40, 123-126.	1.6	15
134	Two PMS2 Mutations in a Turcot Syndrome Family with Small Bowel Cancers. <i>American Journal of Gastroenterology</i> , 2005, 100, 1886-1891.	0.4	65
135	Genetic Heterogeneity of Variable Number Tandem Repeats in Thymidylate Synthase Gene in Colorectal Cancer Patients. <i>International Journal of Biological Markers</i> , 2004, 19, 332-336.	1.8	4
136	Neoadjuvant treatment for locally advanced rectal carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2004, 52, 61-71.	4.4	11
137	Genetic heterogeneity of variable number tandem repeats in thymidylate synthase gene in colorectal cancer patients. <i>International Journal of Biological Markers</i> , 2004, 19, 332-336.	1.8	4
138	Early-Age-at-Onset Colorectal Cancer and Microsatellite Instability as Markers of Hereditary Nonpolyposis Colorectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2003, 46, 305-312.	1.3	22
139	Amiodarone inhibits lung degradation of SP-A and perturbs the distribution of lysosomal enzymes. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2001, 281, L1189-L1199.	2.9	33
140	Optimization of Biomimetic, Leukocyte-Mimicking Nanovesicles for Drug Delivery Against Colorectal Cancer Using a Design of Experiment Approach. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	4.1	4